Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | STK4 | Q13043 | 1/20 | 0.35 |
| ▸ | STK3 | Q13188 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491628 | 0.85 | AKT2 (0.43) | KITLRRK2IRAK4IRAK1 | |
| SCHEMBL3494086 | 0.84 | LRRK2 (0.41) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL3490733 | 0.84 | LRRK2 (0.41) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL3492904 | 0.83 | LRRK2 (0.41) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL3492388 | 0.83 | LRRK2 (0.41) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL3493174 | 0.83 | LRRK2 (0.41) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL3492315 | 0.82 | LRRK2 (0.40) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL3492317 | 0.82 | LRRK2 (0.40) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL3495229 | 0.82 | LRRK2 (0.40) | KITLRRK2IRAK4IRAK1STK4 | |
| SCHEMBL4443648 | 0.81 | LRRK2 (0.45) | LRRK2STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| CN-101627042-A | Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety | ASTEX THERAPEUTICS LTD | 2010-01-13 | — | — | CN | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | KIT 1421/4885LRRK2 1684/4885IRAK4 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.